Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Telix Pharmaceuticals ( (AU:TLX) ) has shared an announcement.
Challenger Limited has announced that it has ceased to be a substantial holder in Telix Pharmaceuticals Ltd. This change in holding status was officially communicated to the ASX, indicating a shift in Challenger’s investment strategy or portfolio composition regarding Telix Pharmaceuticals. The announcement may impact stakeholders by altering the perceived market position or investment appeal of Telix Pharmaceuticals.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$23.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Average Trading Volume: 2,484,951
Technical Sentiment Signal: Sell
Current Market Cap: A$4.66B
For a thorough assessment of TLX stock, go to TipRanks’ Stock Analysis page.